FDA Upgrades Recall on 160,000+ Bottles of Thyroid Medication
By Denise Mann HealthDay Reporter
THURSDAY, July 24, 2025 — The U.S. Food and Drug Administration (FDA) has upgraded a recall of a commonly prescribed thyroid medication due to what it described as "subpotent" active ingredients.
The recall of more than 160,000 bottles of levothyroxine sodium, which went into effect June 20, was upgraded to a Class II recall on July 23. Class II recalls occur when use of the drug poses a moderate public health risk, according to the FDA.
The recall was initiated because the medication content of the recalled pills is “below the approved specification,” according to the New York-based television network NTD.
No other details were available about the recall, including whether anyone has become ill from the weak pills.
Levothyroxine sodium is used to treat a sluggish thyroid gland (hypothyroidism). Left untreated, hypothyroidism can lead to heart problems and high cholesterol, among other issues, according to the Mayo Clinic..
The recalled drugs are manufactured by India-based Intas Pharmaceuticals for North Carolina-based Accord Healthcare, NTD reported. They total 160,630 bottles and come in various doses, strengths, and packages, including:
-
Lot D2400536; expiration date, Feb. 28, 2026
-
Lot D2300325; expiration date, Jan. 31, 2026
-
Lot D2400679; expiration date, Feb. 28, 2026
-
Lot D2300087; expiration date, Dec. 31, 2025
-
Lot D2300092; expiration date, Dec. 31, 2025
-
Lot D2400722; expiration date, March 31, 2026
-
Lot D2300104; expiration date, Dec. 31, 2025
-
Lot D2300076; expiration date, Dec. 31, 2025
-
Lot D2300042; expiration date, Dec. 31, 2025
Sources
- U.S. Food and Drug Administration, alert, July 23, 2025
- NTD, July 23, 2025
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2025
Read this next
FDA to Review and Possibly Ban Fluoride Supplements for Kids
WEDNESDAY, May 14, 2025 — The U.S. Food and Drug Administration (FDA) plans to review and possibly remove prescription fluoride supplements for children from the...
Could the Common Thyroid Medicine Levothyroxine Weaken Bones?
MONDAY, Nov. 25, 2024 -- New research suggests that a thyroid medication often prescribed to older Americans may be linked to a common problem in old age -- bone...
Hidden Thyroid Issues in Pregnancy Could Mean Thyroid Trouble Later
TUESDAY, Aug 6, 2024 -- Women who develop subclinical thyroid issues during pregnancy, meaning symptoms haven't surfaced, could face real thyroid trouble within five years, a new...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.